Skip to main content

Govt talking to Russia for possible Advancement of its Covid-19 Vaccine here: Health Ministry

By Unknown

The Centre is in consultations with the Russian government for exploring the possibility of cooperation between the two countries for advancing the Covid-19 vaccine in India, Parliament was told on Friday.

The Central Drugs Standard Control Organisation (CDSCO) has informed that it has received information about one Covid-19 vaccine developed and approved in Russia,  Minister of State for Health Ashwini Choubey informed the Lok Sabha.   

Further, the Indian Council of Medical Research (ICMR), an autonomous organisation under the Department of Health Research, has informed that as per information available from WHO draft landscape of Covid-19 vaccine (last updated on September 17), globally there are 36 candidate vaccines which are under various stages of clinical trials. 

"Of this only 02 are Indian candidates (Bharat Biotech International Ltd. and Cadila Healthcare). All 36 candidates are under various stages of clinical trials. None of the candidate vaccines so far has completed all stages of a clinical trial," he said in a written reply.

In response to a question on whether the government is in talks with Russia and other countries to procure Covid-19 vaccine doses in the upcoming months, Choubey said, "The Department of Biotechnology has informed that the Government of India is in consultations with the Russian Government for exploring the possibility of cooperation with Russia for advancing Covid-19 Vaccine in India."

Further, Phase II and III bridging studies of ChAdOx1-S, a vaccine developed by University of Oxford/AstraZeneca have been initiated in India.

"While the government and industry are trying their best to make available a safe and effective vaccine for Covid-19 at the earliest, it is difficult to comment on the exact timelines in view of various complex pathways involved in vaccine development," the minister underlined.

Elaborating on the steps taken by the government for timely availability of Covid-19 drugs and vaccination, Choubey informed that CDSCO has approved the manufacturing and marketing of three drugs --- Remdesivir Injectable formulations, Favipiravir tablets, Itolizumab injection -- for restricted emergency use in the country for treatment of coronavirus infection.

Further, the CDSCO has granted permission for conduct of phase I and II clinical trials of the two vaccine candidates indigenously developed by Bharat Biotech in collaboration with ICMR and Cadila Healthcare Ltd.

Besides, it has also given permission to the Serum Institute of India to conduct phase II and III clinical trial of the Oxford Covid-19 vaccine, the minister said.


Comments

Post a Comment

Popular posts from this blog

Increased risks of drop out for women and girls : CoronaVirus Updates

By Unknown
The total number of children not returning to their education after the school closures is likely to be significant. The pandemic also risks jeopardizing some of the gains made since 2001 in re-building women and girls’ education following the Taliban regime.  The COVID-19 pandemic is creating additional barriers due to risks—and students’ and parents’ anxiety about risks—associated with children returning to classrooms that are cramped, with no capacity for distancing, often cold, damp and poorly ventilated during the country’s severe winters, and have no or poor hygiene and clean water facilities. The COVID-19 pandemic is likely to drive many women and girls out of education permanently. School closures due to COVID-19, resulting increases in caregiving responsibilities for women and girls, and increases in poverty and unemployment will all make it harder for women and girls to study.  These factors combine in harmful ways with pre-existing discriminatory gender norms, o...
Post a Comment
Read more

No significant benefit of Umifenovir in COVID-19 treatment: Glenmark

By Unknown
Drug firm  Glenmark Pharmaceuticals  on Friday said the addition of  antiviral Umifenovir  did not demonstrate any significant clinical benefit over  Favipiravir  alone in  moderate COVID-19 patients .  The  clinical study  evaluated the possible superiority of the combination's efficacy against Favipiravir monotherapy, Glenmark said in a statement. As per the results that Glenmark presented to the regulator, the study showed no superior clinical outcomes with the addition of Umifenovir, it added. This was the second clinical study after the successful Favipiravir monotherapy trial earlier this year that led the company to receiving the Emergency Use Authorisation for Favipiravir, Glenmark said. "These latest findings confirm that the addition of Umifenovir does not show any incremental benefit in clinical outcomes. Thus Favipiravir therapy along with supportive care remains a suitable and effective choice for mild to moderate COVID-1...
Post a Comment
Read more

Context & pre-existing barriers to education for girls and women

By Unknown
Education is a right for all children and an educated population is essential for building a self-reliant, peaceful, equal, and inclusive Afghan society. Afghanistan’s education system has been severely impacted by decades of conflict, widespread poverty and humanitarian crisis.  Today, funding remains insufficient, as only 3% of Afghanistan’s Gross Domestic Product is allocated to education. International standards state that the government should spend at least 4 to 6% of GDP on education.  The Incheon Declaration and Framework for Action for the implementation of Sustainable Development Goal 4 recognizes that to “ensure inclusive and equitable quality education and promote lifelong learning opportunities for all”, least developed countries need to dedicate at least or more than 4 to 6%.  Afghanistan budgets far less than this, and even with this small percentage of funding the country’s education budget continues to be underspent every year.Afghanistan has one of the y...
Post a Comment
Read more